Allergy/Imm Medical News about Immunotherapy

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Novel therapies for children with severe asthma

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Toward effective immunotherapy for the treatment of malignant brain tumors
Neurotherapeutics, 07/01/09

Mitchell DA et al. - In a review of effective immunotherapy for treatment of malignant brain tumors (MBTs), this article will focus on some of the most important breakthroughs in understanding of how to generate potent anti-tumor immune responses, and some of the challenges that lie ahead in achieving effective immunotherapy for the majority of pts with MBTs.

Methods

Immunologic treatment of cancer has long been heralded as a targeted molecular therapeutic with the promise of eradicating tumor cells with minimal damage to surrounding normal tissues.
A demonstrative example of the efficacy of immunotherapy in modulating cancer progression is still lacking for most human cancers.
Recent breakthroughs in understanding of the mechanisms leading to full T-cell activation, and recognition of the importance of overcoming tumor-induced immunosuppressive mechanisms, have shed new light on how to generate effective anti-tumor immune responses in humans, and sparked a renewed and enthusiastic effort to realize the full potential of cancer immunotherapy.

Results

Immunologic treatment of invasive MBTs has not escaped this re-invigorated endeavor, and promising therapies are currently under active investigation in dozens of clinical trials at several institutions worldwide.
A review of immunotherapeutic strategies currently under clinical evaluation, as well as an outline of promising novel approaches on the horizon, is included to provide perspective on the active and stalwart progress toward effective immunotherapy for the treatment of MBTs.

<< Previous
Evolution of CD4+ T Cell Count in HIV-1-Infected Adults Receiving...

Next >>
Near Full-Length Genome Characterization of an HIV-1 CRF01_AE...